Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05636085

Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma

This study is to determine how the Mainz Biomed Colorectal Cancer Screening Test works when used in people aged ≥45 years of age and at an average risk of developing colorectal cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This study is to validate the clinical performance for the Mainz Biomed Colorectal Cancer Screening Test in an average risk population aged ≥45 years of age.

Stool samples will be collected from subjects ≥45 years of age, of average risk for colon cancer, and scheduled to have a screening colonoscopy. The samples will be collected prior to colonoscopy and will be tested with the Mainz Biomed Colorectal Cancer Screening Test. The results will be compared with colonoscopy results to determine test performance.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is any sex and ≥45 years of age
  • Subject must be advised to have or be scheduled for a screening colonoscopy
  • Subject is at average risk for colorectal cancer according to the United States Preventive Services Task Force (USPSTF) guidelines, including:
  • no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease
  • no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer including:
  • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease
  • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP)
  • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome")
  • Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis and Familial Hyperplastic Polyposis
  • Cronkhite Canada Syndrome
  • Subject can understand the study procedures and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form
  • Subject is able and willing to provide stool samples within ninety (90) days before the colonoscopy procedure
  • Subject is able and willing to undergo a colonoscopy after providing a stool sample

Exclusion criteria

  • Subject had any precancerous findings on most recent colonoscopy.
  • Subject has a history of abnormal imaging suggesting colorectal cancer (e.g., colonography, MRI, CT, barium enema)
  • Subject has a history of any of the following cancers: oral, head and neck, lung, esophagus, gastric, biliary/liver, pancreatic, small bowel, or appendiceal
  • Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals
  • High-sensitivity fecal occult blood test or fecal immunochemical test within the previous twelve (12) months
  • sDNA-FIT test within the previous thirty-six (36) months
  • Subject has had a colonoscopy in the previous nine (9) years
  • Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease
  • Indication for colonoscopy due to overt rectal bleeding (e.g., hematochezia or melena) within the previous thirty (30) days
  • Subject has any condition that in the opinion of the investigator should preclude participation in the study

Treatment and study plan

Mainz Biomed Colorectal Cancer Screening Test

Device

There is no intervention.

Primary outcomes

  1. Sensitivity Colorectal Cancer

    Time frame: 18 to 24 months

    Sensitivity of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer

  2. Sensitivity Advanced Adenoma

    Time frame: 18 to 24 months

    Sensitivity of the Mainz Biomed Colorectal Cancer Screening Test for Advanced Adenoma

  3. Specificity

    Time frame: 18 to 24 months

    Specificity of the Mainz Biomed Colorectal Cancer Screening Test for Advanced Neoplasia

Secondary outcomes

  1. Positive predictive value and negative predictive value

    Time frame: 18 to 24 months

    Determine the positive predictive value and negative predictive value for the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer, Advanced Adenoma, and Advanced Neoplasia

Study contacts

Contact information is provided by the study sponsor or research team.

Christian Von Toerne, PhD

CONTACT

[email protected]

+49 (0) 173 1621928

Lena Krammes, PhD

CONTACT

[email protected]

+49 (0) 613126514-18

Sponsors and collaborators

Lead sponsor

Mainz Biomed

Industry

Registry information

Official study title

Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for the Detection of Colorectal Cancer and Advanced Adenoma in an Average Risk Population

Acronym: reconAAsense

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 5, 2022
Registry last updated
Mar 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.